Developer docs
API playgroundTry for free, no card

Search company profiles

baCta

Full company profile

uuid0002nzv

Namestring
baCta
Legal namestring
baCta
Websiteurl
bacta.life
Company typeenum
Private
Founded yearint
2024
Short descriptiontext

Paris-based industrial biotech startup founded in 2024 that uses AI-powered precision fermentation to engineer yeast as molecular factories producing astaxanthin and other high-value ingredients for cosmetics, human nutrition, and animal nutrition markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision fermentation, synthetic biology, bioproduction platform, industrial biotechnology, bio-based ingredients
Industry3 codes
PRIMARYEUAAAIAA
Bio-based Platform & Commodity Chemicals (e.g., bio-ethylene, bio-propylene, bio-BTX, bio-methanol)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
Product category
Industrial Biotechnology / Bio-based Ingredients
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Industrial Ingredient Sales
TypeOne Time License
Description

Sale of bio-based industrial ingredients (starting with astaxanthin) to cosmetics, human nutrition, and animal nutrition markets through B2B commercial partnerships

finsmes.com
2Platform Licensing
TypeLicensing Royalties
Description

Potential licensing of baCtaForge platform technology to industrial manufacturers for customized bioproduction applications

agfundernews.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1baCtaForge
Description

AI-powered bioproduction platform combining Genome-to-factory AI model, Precision Biofoundry, and full stack bioproduction for strain engineering and industrial fermentation.

bacta.bio
Core offering1 text field

baCta develops and operates baCtaForge, an AI-powered bioproduction platform that uses synthetic biology, robotics, and generative AI to engineer microorganisms as programmable molecular factories for sustainable industrial ingredient manufacturing. The company produces high-value bio-based ingredients via precision fermentation, with Astaxanthin as its first commercial product targeting cosmetics, human nutrition, and animal nutrition markets. The platform combines a Genome-to-Factory AI model, Precision Biofoundry automation, and full-stack bioproduction for end-to-end strain engineering and fermentation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Cell density over 100g/L versus under 5g/L for traditional algae methods
+2 more records
Product overview1 text field

baCta is a Paris-based industrial biotech startup founded in 2024 that has developed baCtaForge, an AI-powered bioproduction platform leveraging synthetic biology, robotics, and generative AI. The platform uses precision fermentation to engineer microorganisms as programmable molecular factories for sustainable production of high-value molecules. The platform consists of three integrated pillars: a Genome-to-Factory AI model that achieves predictive throughput for strain optimization, a Precision Biofoundry combining wet-lab automation with AI for strain engineering, and full-stack bioproduction capabilities for fermentation and downstream processing. The company's first commercial product is Astaxanthin, a high-value antioxidant produced via yeast fermentation, marketed in multiple high-performance forms for cosmetics, human nutrition, and animal nutrition markets.

Product and service4 records
1baCtaForge Platform
CategoryPlatform / Technology
Description

AI-powered bioproduction platform that integrates synthetic biology, robotics, and generative AI to engineer microorganisms as programmable molecular factories for sustainable industrial ingredient manufacturing, structured around three pillars: Genome-to-Factory AI model, Precision Biofoundry, and full-stack bioproduction.

2Astaxanthin
CategoryBio-based ingredient
Description

High-value antioxidant compound produced via AI-optimized yeast fermentation as baCta's first commercial product, marketed to cosmetics, human nutrition, and animal nutrition markets with transparent traceability.

3Cosmetic Ingredients
CategoryBio-based ingredient
Description

High-performance bio-based ingredient forms derived from baCtaForge-produced compounds, available in multiple forms with transparent traceability for cosmetics and personal care brands.

4Nutrition Ingredients
CategoryBio-based ingredient
Description

High-performance bio-based ingredient forms derived from baCtaForge-produced compounds, available in multiple forms with transparent traceability for human nutrition and nutraceutical applications.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1French Industrial Manufacturer
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-03
Description

Strategic partnership with a French industrial manufacturer to access production infrastructure for pilot and commercial-scale validation. Company is in advanced discussions with this partner for scale-up operations.

agfundernews.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based precision fermentation company producing high-value ingredients including astaxanthin via engineered microorganisms. Closest direct comparable to baCta in technology stack (synthetic biology + fermentation), target molecule (astaxanthin), and B2B ingredient commercialization model.

TypeDirect peer
Description

Precision fermentation startup that engineers microorganisms to produce high-value specialty ingredients for flavors, fragrances, cosmetics, and nutrition. Directly comparable to baCta's technology approach (engineered microbial hosts, fermentation scale-up, B2B ingredient sales to CPG customers).

TypeBroad incumbent
Description

Global nutrition and ingredients conglomerate that produces and sells natural astaxanthin (e.g., PARRY/AstaPure brands) plus a broad portfolio of vitamins, carotenoids, and specialty ingredients. Direct incumbent competitor in baCta's target end markets (animal nutrition, nutrition, personal care).

TypeBroad incumbent
Description

Global chemicals giant that produces synthetic astaxanthin (Lucantin) for animal feed and aquaculture, plus a broad portfolio of feed additives and nutrition ingredients. Represents the price benchmark that baCta's fermentation route must beat to gain share in animal nutrition.

TypeBroad incumbent
Description

US-listed synthetic biology platform company that programs microorganisms for ingredient and industrial biotech applications across multiple end markets. Comparable to baCta in technology approach (AI + synbio + foundry automation) but operates as a broad horizontal platform with significantly more capital and scale.

TypeEmerging player
Description

Early-stage precision fermentation company developing microbial bioproduction for nutrition, personal care, and flavors & fragrances. Closely comparable to baCta in stage, technology stack (engineered microbial hosts + fermentation), and target B2B end markets.

TypeDirect peer
Description

Iceland-based producer of natural astaxanthin from microalgae for nutraceuticals, cosmetics, and animal feed. Direct competitor in the same end markets with the same target molecule, though using extraction-based algae cultivation rather than yeast fermentation.

TypeBroad incumbent
Description

Private global ingredient manufacturer supplying antioxidants, pigments, and feed additives for animal nutrition, pet food, and human nutrition. Comparable to baCta as an established B2B ingredient supplier in the same target verticals, particularly animal nutrition.

TypeEmerging player
Description

US-listed carbon capture company using gas fermentation (engineered acetogens) to produce specialty chemicals, fuels, and ingredients from industrial off-gases. Comparable to baCta in core technology (precision fermentation of engineered microbes) and B2B ingredient commercialization, with overlapping end markets in cosmetics and nutrition.

TypeEmerging player
Description

Finnish precision fermentation company producing food ingredients (Solein protein) from CO2 and electricity using engineered microorganisms. Comparable to baCta in technology approach (precision fermentation of engineered microbes for B2B ingredient markets) and in pursuing novel food regulatory pathways.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

baCta

Industrial Biotechnology / Bio-based Ingredientsbacta.life

Paris-based industrial biotech startup founded in 2024 that uses AI-powered precision fermentation to engineer yeast as molecular factories producing astaxanthin and other high-value ingredients for cosmetics, human nutrition, and animal nutrition markets.

baCta firmographics

Firmographics
Name
baCta
Legal name
baCta
Website
https://bacta.life
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Paris-based industrial biotech startup founded in 2024 that uses AI-powered precision fermentation to engineer yeast as molecular factories producing astaxanthin and other high-value ingredients for cosmetics, human nutrition, and animal nutrition markets.
Ownership category
akta.pro rank

baCta industry classification

Industry
Product category
Industrial Biotechnology / Bio-based Ingredients
akta.pro industry
PRIMARYEUAAAIAA
Bio-based Platform & Commodity Chemicals (e.g., bio-ethylene, bio-propylene, bio-BTX, bio-methanol)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Precision fermentation
  • Synthetic biology
  • Bioproduction platform
  • Industrial biotechnology
  • Bio-based ingredients

Where baCta is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

baCta business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Industrial Ingredient Sales: Sale of bio-based industrial ingredients (starting with astaxanthin) to cosmetics, human nutrition, and animal nutrition markets through B2B commercial partnerships
  2. Platform Licensing: Potential licensing of baCtaForge platform technology to industrial manufacturers for customized bioproduction applications

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

baCta product offering

Product offering

Core offering

baCta develops and operates baCtaForge, an AI-powered bioproduction platform that uses synthetic biology, robotics, and generative AI to engineer microorganisms as programmable molecular factories for sustainable industrial ingredient manufacturing. The company produces high-value bio-based ingredients via precision fermentation, with Astaxanthin as its first commercial product targeting cosmetics, human nutrition, and animal nutrition markets. The platform combines a Genome-to-Factory AI model, Precision Biofoundry automation, and full-stack bioproduction for end-to-end strain engineering and fermentation.

Product overview

baCta is a Paris-based industrial biotech startup founded in 2024 that has developed baCtaForge, an AI-powered bioproduction platform leveraging synthetic biology, robotics, and generative AI. The platform uses precision fermentation to engineer microorganisms as programmable molecular factories for sustainable production of high-value molecules. The platform consists of three integrated pillars: a Genome-to-Factory AI model that achieves predictive throughput for strain optimization, a Precision Biofoundry combining wet-lab automation with AI for strain engineering, and full-stack bioproduction capabilities for fermentation and downstream processing. The company's first commercial product is Astaxanthin, a high-value antioxidant produced via yeast fermentation, marketed in multiple high-performance forms for cosmetics, human nutrition, and animal nutrition markets.

Differentiator

Problem solved

Functional benefit

Brands

  • baCtaForge: AI-powered bioproduction platform combining Genome-to-factory AI model, Precision Biofoundry, and full stack bioproduction for strain engineering and industrial fermentation.

Products and services

  • baCtaForge Platform AI-powered bioproduction platform that integrates synthetic biology, robotics, and generative AI to engineer microorganisms as programmable molecular factories for sustainable industrial ingredient manufacturing, structured around three pillars: Genome-to-Factory AI model, Precision Biofoundry, and full-stack bioproduction.
  • Astaxanthin High-value antioxidant compound produced via AI-optimized yeast fermentation as baCta's first commercial product, marketed to cosmetics, human nutrition, and animal nutrition markets with transparent traceability.
  • Cosmetic Ingredients High-performance bio-based ingredient forms derived from baCtaForge-produced compounds, available in multiple forms with transparent traceability for cosmetics and personal care brands.
  • Nutrition Ingredients High-performance bio-based ingredient forms derived from baCtaForge-produced compounds, available in multiple forms with transparent traceability for human nutrition and nutraceutical applications.

Quantifiable outcome

  • Cell density over 100g/L versus under 5g/L for traditional algae methods
  • +2 more outcomes

Companies that use baCta

Customer profile

Segments3 records

Ideal customer profiles3 records

baCta technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

baCta partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • French Industrial ManufacturercoreStrategic or Co-development Partner · 3 March 2026Strategic partnership with a French industrial manufacturer to access production infrastructure for pilot and commercial-scale validation. Company is in advanced discussions with this partner for scale-up operations.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

baCta competitors and assessment

Company assessment

Direct peers

  • Conagen: US-based precision fermentation company producing high-value ingredients including astaxanthin via engineered microorganisms. Closest direct comparable to baCta in technology stack (synthetic biology + fermentation), target molecule (astaxanthin), and B2B ingredient commercialization model.
  • Manus Bio: Precision fermentation startup that engineers microorganisms to produce high-value specialty ingredients for flavors, fragrances, cosmetics, and nutrition. Directly comparable to baCta's technology approach (engineered microbial hosts, fermentation scale-up, B2B ingredient sales to CPG customers).
  • Algalif: Iceland-based producer of natural astaxanthin from microalgae for nutraceuticals, cosmetics, and animal feed. Direct competitor in the same end markets with the same target molecule, though using extraction-based algae cultivation rather than yeast fermentation.

Broad incumbents

  • dsm-firmenich: Global nutrition and ingredients conglomerate that produces and sells natural astaxanthin (e.g., PARRY/AstaPure brands) plus a broad portfolio of vitamins, carotenoids, and specialty ingredients. Direct incumbent competitor in baCta's target end markets (animal nutrition, nutrition, personal care).
  • BASF: Global chemicals giant that produces synthetic astaxanthin (Lucantin) for animal feed and aquaculture, plus a broad portfolio of feed additives and nutrition ingredients. Represents the price benchmark that baCta's fermentation route must beat to gain share in animal nutrition.
  • Ginkgo Bioworks: US-listed synthetic biology platform company that programs microorganisms for ingredient and industrial biotech applications across multiple end markets. Comparable to baCta in technology approach (AI + synbio + foundry automation) but operates as a broad horizontal platform with significantly more capital and scale.
  • Kemin Industries: Private global ingredient manufacturer supplying antioxidants, pigments, and feed additives for animal nutrition, pet food, and human nutrition. Comparable to baCta as an established B2B ingredient supplier in the same target verticals, particularly animal nutrition.

Emerging players

  • Bota Bio: Early-stage precision fermentation company developing microbial bioproduction for nutrition, personal care, and flavors & fragrances. Closely comparable to baCta in stage, technology stack (engineered microbial hosts + fermentation), and target B2B end markets.
  • LanzaTech: US-listed carbon capture company using gas fermentation (engineered acetogens) to produce specialty chemicals, fuels, and ingredients from industrial off-gases. Comparable to baCta in core technology (precision fermentation of engineered microbes) and B2B ingredient commercialization, with overlapping end markets in cosmetics and nutrition.
  • Solar Foods: Finnish precision fermentation company producing food ingredients (Solein protein) from CO2 and electricity using engineered microorganisms. Comparable to baCta in technology approach (precision fermentation of engineered microbes for B2B ingredient markets) and in pursuing novel food regulatory pathways.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

baCta social profiles

Digital presence

baCta financial estimates

Financial estimate

Revenue estimate

Valuation estimate

baCta leadership team

Management profile

Number of profiles

Profiles3 records

baCta funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

baCta M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about baCta

What does baCta do?

baCta develops and operates baCtaForge, an AI-powered bioproduction platform that uses synthetic biology, robotics, and generative AI to engineer microorganisms as programmable molecular factories for sustainable industrial ingredient manufacturing. The company produces high-value bio-based ingredients via precision fermentation, with Astaxanthin as its first commercial product targeting cosmetics, human nutrition, and animal nutrition markets. The platform combines a Genome-to-Factory AI model, Precision Biofoundry automation, and full-stack bioproduction for end-to-end strain engineering and fermentation.

Is baCta a public or private company?

baCta is a private company. It is classified as venture growth investor backed and is currently operating.

When was baCta founded?

baCta was founded in 2024. It employs 11 to 50 people.

Where is baCta based?

baCta is headquartered in Paris, France, in the Europe region.

How does baCta make money?

Two revenue lines are on record. Industrial Ingredient Sales are the primary driver. The others are platform Licensing.

Who are baCta's main competitors?

Direct peers on record are Conagen, Manus Bio and Algalif. Broad incumbents are dsm-firmenich, BASF, Ginkgo Bioworks and Kemin Industries. Emerging players are Bota Bio, LanzaTech and Solar Foods.

Does baCta have an API?

No public API is recorded for baCta.

What industry is baCta in?

baCta's product category is Industrial Biotechnology / Bio-based Ingredients. Its primary akta.pro industry code is EUAAAIAA, Bio-based Platform & Commodity Chemicals (e.g., bio-ethylene, bio-propylene, bio-BTX, bio-methanol), with a secondary code of EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsbaCta Raises €7M in Seed FundingParis-based AI-powered bioproduction company baCta raised €7 million in seed funding, with the round led by LocalGlobe and Daphni along with participation from OVNI Capital and business angels. The company plans to use the funds to advance its first molecule, astaxanthin, and scale its baCtaForge AI-powered bioproduction platform for industrial ingredients. Founded in 2024, baCta leverages generative AI and synthetic biology to develop sustainable, bio-based alternatives to petrochemical-based industrial ingredients through precision fermentation.StartupmafiaParis-Based baCta Raises €7M to Turn Microorganisms into Programmable Molecular FactoriesParis-based biotech startup baCta has secured €7 million in seed funding led by LocalGlobe and Daphni, with participation from OVNI Capital, to advance its baCtaForge platform that engineers microorganisms to produce complex molecules. The company's first commercial target is astaxanthin, a high-value antioxidant, and it plans to use the funding for pilot and commercial-scale production partnerships with industrial manufacturers in France. Beyond this initial product, baCta aims to expand into additional high-value molecules with the goal of replacing extraction-based and petrochemical supply chains with scalable bio-based production systems.Pulse 2.0baCta: €7 Million Raised To Use Microorganisms As Programmable Molecular FactoriesbaCta raised €7 million in seed funding led by LocalGlobe and Daphni to scale production of astaxanthin using engineered microorganisms. The company expects positive unit economics in 2026 and plans commercialization by 2027. It aims to expand its AI-driven platform to produce additional high-value molecules.AgFunderNewsCan fermentation undercut synthetics? baCta chases astaxanthin’s ‘collagen moment’baCta, a Paris-based startup founded in 2024 by Mathieu Nohet and Marie Rouquette, has raised a €7 million ($8.3 million) seed round led by LocalGlobe and Daphni, with participation from OVNI Capital and business angels, to scale fermentation-based production of astaxanthin. The company uses AI and robotics to engineer yeast strains for producing the antioxidant compound, targeting cosmetics and nutraceuticals markets with a goal of achieving costs comparable to synthetic production methods. baCta is in advanced discussions with a French industrial partner for scale-up and plans to pursue GRAS approval in the US and novel food status in the EU.FoundersTodaybaCta secures €7M seed to scale AI-powered industrial bioproduction platformbaCta, a Paris-based industrial biotechnology startup founded in 2024, has secured €7 million in seed funding led by LocalGlobe and Daphni, with participation from OVNI Capital and angel investors. The capital will support pilot and commercial validation of its AI-powered precision fermentation platform (baCtaForge) and scale-up of its first product, astaxanthin, a high-value antioxidant used in health, nutrition, cosmetics, and animal nutrition markets. The company has also established a strategic partnership with a French industrial manufacturer to access production infrastructure.Tech.eubaCta secures €7M to advance programmable microbial factoriesParis-based biotech startup baCta has closed a €7 million seed funding round led by LocalGlobe and Daphni, with participation from OVNI Capital and several business angels. The company develops an AI-powered bioproduction platform called baCtaForge that uses precision fermentation to program microorganisms as molecular factories for sustainable industrial ingredient manufacturing. The funding will be used to scale production through pilot and commercial validation stages, leverage a partnership with a French industrial player, and initiate commercialization of the platform.EU-StartupsParis’ baCta raises €7 million to use microorganisms as programmable molecular factories for industrial ingredientsbaCta, a Paris-based industrial biotech startup, raised €7 million in Seed funding led by LocalGlobe and Daphni, with participation from OVNI Capital, to scale up production of astaxanthin, an antioxidant used in health, nutrition, cosmetics, and animal feed. The company leverages AI and precision fermentation to turn microorganisms into programmable molecular factories for producing industrial ingredients sustainably at commercial scale. The funding will also support expansion of baCtaForge, the company's strain engineering platform combining a Precision Biofoundry and Genome-to-Factory AI model.Tech.eubaCta’s “Docker for cells” creates biosynthetic, carbon-negative rubberbaCta, a French biotech, produces biosynthetic natural rubber using genetically engineered E. coli bacteria. The process is carbon-negative, potentially reducing emissions by up to 151%, and aims to supply high-value products like luxury watches and shoes. The company plans to expand to industrial and automotive components, and later tyres.TechCrunchBaCta is using engineered bacteria to grow natural rubber and slash CO2 emissionsParis-based baCta has a proof-of-concept using engineered E. coli to produce natural rubber in vitro, aiming for a carbon-neutral process. The startup raised €3.3 million in pre-seed funding to scale production from milligrams to industrial quantities. It targets luxury fashion brands first, with pilot scale expected in 18 months.